Table 3.
The safety profiles of PARP inhibitors (olaparib, rucaparib and niraparib) in clinical trials27,31,36,39–43,45
| Drugs | Study | Grade 3/4 AEs | Dose interruption | Dose reduction | Dose discontinuation | MDS/AML | Treatment related deaths |
|---|---|---|---|---|---|---|---|
| Olaparib | Study2/24/9/ 12/20/42(n=223) | 54% | 40% | 4% | 7% | 2% | 3.6% |
| Study19(n=136) | 35.3% | 27.9% | 22.8% | 2.2% | 2% | 0% | |
| SOLO2(n=195) | 36% | 45% | 25% | 11% | 2% | 1% | |
| SOLO1(n=260) | 39% | 52% | 28% | 12% | 1% | 0% | |
| Rucaparib | ARIEL2 + Study10(n=377) | 60.7% | 58.6% | 45.9% | 10% | 0.5% | 0% |
| ARIEL3(n=372) | 56% | 64% | 55% | 13% | 1% | 1% | |
| Niraparib | NOVA(n=367) | 64.6% | 68.9% | 66.5% | 14.7% | 1.4% | 0.3% |
Abbreviations: AEs, Adverse Events; MDS/AML, myelodysplastic syndrome/acute myeloid leukemia; PARP, poly (ADP-ribose) polymerase.